Clinical Trial Update: Study to Assess the Safety, Tolerability, and Effects of CHI-202 to Support Recovery From Physical Activity [Phase 2]

View source ↗

Summary

A Phase 2 trial assessing safety, tolerability, and effects of CHI-202 for recovery from physical activity afterDelayed Onset Muscle Soreness (DOMS) completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Delayed-onset Muscle Soreness

Drugs mentioned

• CHI-202

Snippet

Sponsor: Canopy Growth Corporation | Conditions: Delayed Onset Muscle Soreness (DOMS) | Phase 2 | Status: COMPLETED